We Can Cure Cancer Without Cutting—So Why Aren’t We? - (Part 1)

Описание: Revolutionizing Cancer Treatment: Intratumoral Immunotherapy + Ablation

Join Dr Nathan Goodyear’s Newsletter ➡️ https://pre-scribed.com/subscribe/

In this groundbreaking episode, Dr. Nathan Goodyear sits down with Dr. Jason Williams to reveal how the fusion of intratumoral ablation and immunotherapy is changing cancer care forever. From the power of precision medicine to the future role of AI and robotics in oncology, this conversation unpacks the science, strategy, and staggering success stories behind personalized tumor treatment.

What You'll Learn in This Episode:

1. Why partial ablation may outperform complete tumor destruction
2. How timing, tumor temperature, and circadian rhythms affect immune response
3. How intratumoral injections deliver targeted results with fewer side effects
4. The role of pulse electric field (PEF) therapy in converting cold tumors to hot
5. Why systemic immune activation is possible—without systemic side effects
6. This isn't one-size-fits-all medicine. It’s integrative innovation at its finest.

Memorable Sound Bites:

"Ablation is just another immunotherapy agent."
"Cold tumors require manipulation to become immune responsive."
"We’re not following a protocol. We’re painting a Picasso with medicine."
"Why would they just choose ablation?"
"Cancer hijacks the immune system—we take it back."

If you're a patient, a provider, or someone who refuses to accept the status quo in oncology—this episode is your wake-up call. From necrosis vs. apoptosis to PEF’s immunogenic advantage, you’ll walk away understanding why intratumoral therapy is the future of cancer care.

Learn More:

Williams Cancer Institute: http://williamscancerinstitute.com

“The Immunotherapy Revolution” by Dr. Jason Williams: https://williamscancerinstitute.com/t...

References

Qian, L., Xie, L., Zhu, Y., Huang, C., & Meng, Z. (2024). Potent induction of antitumor immunity by combining cryo-thermal ablation with immune checkpoint inhibitors in hepatocellular carcinoma. Liver International, 44(3), 723–737. https://doi.org/10.1111/liv.15817

Seguin, J., El Hajjam, M., Legagneux, J., Diakhaby, S., Mignet, N., Boudy, V., Toussaint, B., Peschaud, F., Emile, J. F., Capron, C., & Malafosse, R. (2024). Radiofrequency combined with intratumoral immunotherapy: Preclinical results and safety in metastatic colorectal carcinoma. Pharmaceutics, 16(3), 315. https://doi.org/10.3390/pharmaceutics...

Pastori, C., Nafie, E. H. O., Wagh, M. S., Mammarappallil, J. G., & Neal, R. E. (2024). Pulsed electric field ablation versus radiofrequency thermal ablation in murine breast cancer models: Anticancer immune stimulation, tumor response, and abscopal effects. Journal of Vascular and Interventional Radiology, 35(3), 442–451.e7. https://doi.org/10.1016/j.jvir.2023.1...

Arciga, B. M., Walters, D. M., Kimchi, E. T., Staveley-O'Carroll, K. F., Li, G., Teixeiro, E., Rachagani, S., & Kaifi, J. T. (2025). Pulsed electric field ablation as a candidate to enhance the anti-tumor immune response to immune checkpoint inhibitors. Cancer Letters, 609, 217361. https://doi.org/10.1016/j.canlet.2024...

Nuccitelli, R. (2019). Application of pulsed electric fields to cancer therapy. Bioelectricity, 1(1), 30–34. https://doi.org/10.1089/bioe.2018.0001

Mustafa, A. R., Miyasato, D., & Wehrenberg-Klee, E. (2024). Synergizing thermal ablation modalities with immunotherapy: Enough to induce systemic antitumoral immunity? Journal of Vascular and Interventional Radiology, 35(2), 185–197. https://doi.org/10.1016/j.jvir.2023.1...

Marabelle, A., Tselikas, L., de Baere, T., & Houot, R. (2017). Intratumoral immunotherapy: Using the tumor as the remedy. Annals of Oncology, 28(suppl_12), xii33–xii43. https://doi.org/10.1093/annonc/mdx683